GSK
GlaxoSmithKline PLC ADR
NYSE: GSK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$52.31
+1.77% today
Updated 2026-04-30
Market cap
$108.66B
P/E ratio
14.52
P/S ratio
3.33x
EPS (TTM)
$3.75
Dividend yield
3.26%
52W range
$34 – $61
Volume
4.7M
GlaxoSmithKline PLC ADR (GSK) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+12.5%
Last 4 quarters
Revenue YoY growth
+1.5%
Most recent quarter
EPS YoY growth
+4.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.8%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+10.9%
2026-02-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-29 | $1.26 | +4.7% | $54.47 | $52.31 | -4.0% |
| 2026-02-04 | $0.70 | +9.3% | $53.34 | $59.17 | +10.9% |
| 2025-10-29 | $1.46 | +24.5% | $43.70 | $46.94 | +7.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $1.20 | $1.26 | +4.7% | $7.63B | +1.5% |
| 2025-12-31 | $0.64 | $0.70 | +9.3% | $8.62B | +6.2% |
| 2025-09-30 | $1.17 | $1.46 | +24.5% | $8.55B | +6.7% |
| 2025-06-30 | $1.11 | $1.24 | +11.7% | $7.99B | +1.3% |
| 2025-03-31 | $1.04 | $1.20 | +15.4% | $7.52B | +2.1% |
| 2024-12-31 | $0.49 | $0.58 | +18.4% | $8.12B | +0.8% |
| 2024-09-30 | $1.16 | $1.29 | +11.2% | $8.01B | -1.7% |
| 2024-06-30 | $0.99 | $1.10 | +11.1% | $7.88B | +9.8% |
| 2024-03-31 | $0.91 | $1.09 | +19.8% | $7.36B | — |
| 2023-12-31 | $0.76 | $0.72 | -5.3% | $8.05B | — |
| 2023-09-30 | $1.14 | $1.28 | +12.3% | $8.15B | — |
| 2023-06-30 | $0.87 | $0.97 | +11.5% | $7.18B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $2.57 | $47.8B | +6.7% | 24 | high |
| 2027 (E) | $2.78 | $50.3B | +5.2% | 24 | high |
| 2029 (E) | $3.38 | $56.8B | +6.7% | 24 | medium |
| 2030 (E) | $3.72 | $60.5B | +6.3% | 24 | medium |
Frequently asked questions
Has GlaxoSmithKline PLC ADR beaten earnings estimates?
GlaxoSmithKline PLC ADR has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +12.5% over the last 4 quarters.
How does GSK stock react to earnings?
GSK stock has moved an average of +4.8% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is GlaxoSmithKline PLC ADR's revenue growth rate?
GlaxoSmithKline PLC ADR reported year-over-year revenue growth of +1.5% in its most recent quarter, with EPS growing +4.7% year-over-year.
What is the expected EPS for GSK in 2026?
Analysts expect GlaxoSmithKline PLC ADR to report EPS of $2.57 for fiscal year 2026, on revenue of $47.8B, based on estimates from 24 analysts.